Navigation Links
Ranbaxy Receives Final Approval to Manufacture and Market Glycopyrrolate Tablets
Date:8/24/2009

PRINCETON, N.J., Aug. 24 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received approval from the U.S. Food and Drug Administration to manufacture and market Glycopyrrolate Tablets USP, 1 mg and 2 mg. The Office of Generic Drugs, U.S. Food and Drug Administration, has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Robinul(R) 1 mg and Robinul(R) Forte Tablets, 2 mg, respectively, of Sciele Pharma, Inc. Total annual market sales for Glycopyrrolate Tablets were $26 million (IMS - MAT: June 2009). Glycopyrrolate Tablets are indicated for use as adjunctive therapy in the treatment of peptic ulcer.

"We are pleased to receive this final approval for Glycopyrrolate Tablets. This product formulation will be launched in the October - December quarter to all classes of trade and further expands the number of affordable generic product formulations offered by RPI, that will be of benefit to patients, healthcare professionals and the U.S. healthcare system," according to Jim Meehan, Vice President of Sales and Distribution for RPI.

Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India's largest pharmaceutical company. RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. healthcare system.

Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies", resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 11 countries. Ranbaxy is a subsidiary of Daiichi Sankyo Company, Ltd.

*Robinul(R) is a registered trademark of Sciele Pharma, Inc.

    CONTACTS:  Charles M. Caprariello
               Vice President, Corporate Communications
               Ranbaxy Inc.
               (609) 720-5615

               Edwige Buteau
               RF Binder Partners Inc.
               (212) 994-7517

               Andrea Pavone
               RF Binder Partners Inc.
               (212) 994-7568


'/>"/>
SOURCE Ranbaxy Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
2. Ranbaxy Gains Approval to Manufacture and Market Carvedilol Tablets in the U.S. Market
3. Ranbaxy First to Gain Approval to Manufacture and Market Clarithromycin for Oral Suspension, USP
4. Ranbaxy Receives Tentative Approval For Valsartan Tablets
5. Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Tablets (OTC), 5mg and 10mg
6. Ranbaxy Gains Approval to Manufacture and Market Cefuroxime Axetil for Oral Suspension
7. Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Oral Solution
8. Ranbaxy to Bring in Daiichi Sankyo as Majority Partner; Strategic Combination Creates Innovator and Generic Pharma Powerhouse
9. Ranbaxy and Pfizer Settle Lipitor Litigation Worldwide
10. Cipher Pharmaceuticals announces U.S. distribution and supply agreement with Ranbaxy for CIP-ISOTRETINOIN
11. Press Statement Issued by Ranbaxy Laboratories Limited
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... ... February 17, 2017 , ... Park Cities Pet Sitter President, Joette White, ... Pet Life Radio network. The episode, which was posted this week, features a ... factors led to Park Cities Pet Sitter’s being awarded the 2017 National Association of ...
(Date:2/17/2017)... NC (PRWEB) , ... February 17, 2017 , ... Smiles ... Commons Shopping Center in Davidson, NC. Dr. Brian Seese leads the practice as a ... dental services under one roof. Smiles by Seese serves patients of all ages with ...
(Date:2/17/2017)... ... February 17, 2017 , ... Wells Pharmacy Network offers ... of controlled and non-controlled substances plus the ability to manage orders on their ... States now accept electronic prescriptions, according to the Office of the National Coordinator ...
(Date:2/17/2017)... Palos Verdes, CA (PRWEB) , ... February 17, ... ... and emotional flow is Dr. Carol Francis' goals for each and ... Retreat Conference, Dr. Carol Francis will demonstrate five different brainwave tools which help ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... HIMSS17 Conference & Exhibition in Orlando, Fla., February 19-23. Visitors to the company’s ... most widely used electronic patient signatures solution in healthcare . , ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... -- On Thursday, February 16, 2017, the ... the closing bell, while the Dow Jones Industrial Average ... five out of nine sectors ended Thursday,s trading session ... Stock-Callers.com assessed the following Medical Appliances & Equipment equities ... SNN ), ABIOMED Inc. (NASDAQ: ABMD ), ...
(Date:2/16/2017)... EXTON, Pa. , Feb. 16, 2017 ... drugs, biologics, and medical devices, is pleased to announce ... Ph.D., has been selected as a winner of the ... SmartCEO Magazine and recognizes driven executives for ... undeniable work ethic. The awards ceremony and celebration is ...
(Date:2/16/2017)... , Feb. 16, 2017 Quest Diagnostics (NYSE: ... diagnostic information services, today announced that it has been ... 2017 by Fortune. The annual survey ... in the "Health Care: Pharmacy and Other Services" industry ... information services company to attain the designation. This is ...
Breaking Medicine Technology: